Andere Sprachen PureTech Health plc

Aktien

A14VK6

GB00BY2Z0H74

PRTC

Markt geschlossen - London S.E. Andere Börsenplätze 17:35:20 26.04.2024			% 5 Tage	% 1. Jan.
218 ^GBX	+2,59 %		+5,57 %	+12,26 %

25.04.	Transcript : PureTech Health plc, 2023 Earnings Call, Apr 25, 2024
25.04.	PureTech spricht von "Schwung", während die Zuschüsse schrumpfen, aber der Jahresverlust sinkt	AN

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

PureTech Health : Proxy Form for 2024 AGM	25.04.
PureTech Health : Notice of Meeting for 2024 AGM	25.04.
PureTech Announces Annual Results for Year Ended December 31, 2023	25.04.
PureTech touts "momentum" as grants shrivel but annual loss narrows	25.04.
Miner Anglo American reviews takeover bid from rival BHP	25.04.
Miner Anglo American eyes rival BHP takeover	25.04.
Correction: Earnings Flash (PRTC.L) PURETECH HEALTH Posts FY23 Loss $-0.24	25.04.
Earnings Flash (PRTC.L) PURETECH HEALTH Reports FY23 Revenue $3.3M	25.04.
Earnings Flash (PRTC.L) PURETECH HEALTH Posts FY24 Loss $-0.24	25.04.
PureTech Health plc Reports Earnings Results for the Full Year Ended December 31, 2023	25.04.
PureTech Health plc - Notice of Results	19.04.
PureTech Health: Notice of Results	18.04.
PureTech Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 in Idiopathic Pulmonary Fibrosis	17.04.
EARNINGS AND TRADING: J Smart boosts revenue, Tertiary starts drilling	16.04.
PureTech Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis	16.04.
PureTech Health plc Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis	16.04.
US FDA hands fast track to PureTech head and neck cancer treatment	11.04.
PureTech Receives FDA Fast Track Designation for LYT-200 in Head and Neck Cancers	11.04.
PureTech Health plc Receives FDA Fast Track Designation for LYT-200 in Head and Neck Cancers	11.04.
Seaport Therapeutics Launches with $100 Million Oversubscribed Series a Financing Round to Advance Novel Neuropsychiatric Medicines	10.04.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen PureTech Health plc

Aktien

A14VK6

GB00BY2Z0H74

PRTC

Andere Sprachen

Filter